- Home
- INVA
INVA
Innoviva Inc.
as 04-01-2025 4:00pm EST
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | BURLINGAME |
| Market Cap: | N/A | IPO Year: | 2004 |
| Target Price: | $55.00 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.36 | EPS Growth: | -83.56 |
| 52 Week Low/High: | $14.33 - $21.28 | Next Earning Date: | 05-07-2025 |
| Revenue: | $358,711,000 | Revenue Growth: | 15.54% |
| Revenue Growth (this year): | -2.19% | Revenue Growth (next year): | 5.81% |
Stock Insider Trading Activity of Innoviva Inc. (INVA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| DENNER ALEXANDER J | INVA | 10% Owner | Mar 4 '25 | Sell | $17.59 | 1,618,295 | $28,395,442.43 | 7,125,825 |
Latest Innoviva Inc. News
INVA Breaking Stock News: Dive into INVA Ticker-Specific Updates for Smart Investing
Argus Research
7 days ago
INVA: What does Argus have to say about INVA?
Barrons.com
11 days ago
Victoria’s Secret, Bitdeer, and More Stocks See Activist Action
Barrons.com
18 days ago
WEX, Lamb Weston, and More Stocks See Action From Activist Investors
MT Newswires
20 days ago
Armata Pharmaceuticals Enters $10 Million Secured Credit Agreement with Innoviva
PR Newswire
21 days ago
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva
MT Newswires
a month ago
Innoviva Insider Sold Shares Worth $28,395,442, According to a Recent SEC Filing
Business Wire
a month ago
Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference
Argus Research
a month ago
INVA: Lowering target price to $18.00
Compare INVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INVA Innoviva Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.